New research suggests that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional diet and exercise plans.
Findings released in a leading medical journal shows that while obese people can lose substantial amounts of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Users buying such medications need to be informed of the potential of quick weight regain when the medication ends," cautioned researcher Dr. Susan Jebb.
This pace of recovery means a return to starting weight within about a year and a half.
Analyzing Approaches
The research, which reviewed dozens of studies involving thousands of participants, compared the results of the injectable medications with other pills.
Researchers note that individuals who shed pounds through dieting usually have a slower weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Nutrition scientists believe the way of the drugs explains the amplified rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal could lead to the system to produce less of its endogenous hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making excessive eating far more likely."
A Lifelong Issue?
Medical guidelines suggest the injections for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals contend that, due to the likelihood of relapse, the treatment should be considered ongoing.
This opinion is supported by drug manufacturers, who state that the findings "underscore the chronic character of excess weight," akin to managing diseases like hypertension.
User Experiences
Users who have stopped the medication explain a intense resurgence of appetite.
"I experienced a trigger flipping and you're instantly starving," recalled one woman.
This difficulty is compounded if individuals have not developed sustainable lifestyle or habit modifications during therapy.
Widespread Use
Recent estimates indicate that millions of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is greater among females compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while these medications are potent agents for weight loss, they are not a standalone solution and maintained weight loss relies on combined lifestyle management.
